Tafas v. Dudas et al

Filing 33

MOTION for Leave to File an Amicus Curiae Brief by Pharmaceutical Research and Manufacturers of America. (Attachments: # 1 Memorandum in Support of Motion for Leave To File an Amicus Curiae Brief# 2 Proposed Order)(Dowd, James)

Tafas v. Dudas et al

Doc. 33

Case 1:07-cv-00846-JCC-TRJ

Document 33

Filed 10/26/2007

Page 1 of 3

UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA (Alexandria Division) ____________________________________ ) TRIANTAFYLLOS TAFAS, ) ) Plaintiff, ) No. 1:07cv846-JCC-TRJ ) v. ) ) JON W. DUDAS et al., ) ) Defendants. ) ) ____________________________________) ) SMITHKLINE BEECHAM ) CORPORATION et al., ) ) No. 1:07cv1008-JCC-TRJ Plaintiffs, ) ) v. ) ) JON W. DUDAS et al., ) ) Defendants. ) ) ____________________________________) MOTION OF PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA FOR LEAVE TO FILE AN AMICUS CURIAE BRIEF The Pharmaceutical Research and Manufacturers of America ("PhRMA") respectfully moves for leave to file a brief as amicus curiae in support of anticipated motions for summary judgment by the plaintiffs in the above-captioned consolidated cases. Counsel for PhRMA have conferred with counsel for Plaintiff Triantafyllos Tafas, the GlaxoSmithKline plaintiffs ("GSK"), and Defendants regarding this motion. Plaintiffs do not oppose this motion, and Defendants take no position on this motion. All parties agree, however, that the motion should be decided without oral argument. 1

Dockets.Justia.com

Case 1:07-cv-00846-JCC-TRJ

Document 33

Filed 10/26/2007

Page 2 of 3

As explained in further detail in the accompanying memorandum, PhRMA and its members--the country's leading research-based pharmaceutical and biotechnology companies-- have a direct interest in this litigation. In light of the current schedule and need for expedited resolution of GSK's pending motion for a TRO and preliminary injunction, PhRMA seeks leave to file an amicus brief in connection with the anticipated summary judgment motions and not GSK's currently pending motion. If the schedule currently in place in the Tafas case is adopted in the GSK case, PhRMA requests that its amicus brief be due on November 14, 2007. If the Tafas schedule is modified or a different schedule is adopted in the GSK case, PhRMA requests that its brief be due one week after GSK files its summary judgment motion. Date: October 26, 2007 David W. Ogden William G. McElwain Randolph D. Moss Brian M. Boynton WILMER CUTLER PICKERING HALE AND DORR LLP 1875 Pennsylvania Avenue, N.W. Washington, D.C. 20006 Tel.: [phone] Fax: [phone] Of Counsel for Pharmaceutical Research and Manufacturers of America Respectfully submitted, __________/s/________________ James M. Dowd (VSB # 41406) WILMER CUTLER PICKERING HALE AND DORR LLP 1875 Pennsylvania Avenue, N.W. Washington, D.C. 20006 Tel.: [phone] Fax: [phone] [e-mail] Attorney for Pharmaceutical Research and Manufacturers of America

2

Case 1:07-cv-00846-JCC-TRJ

Document 33

Filed 10/26/2007

Page 3 of 3

CERTIFICATE OF SERVICE I hereby certify that on October 26, 2007, the foregoing pleading was electronically filed with the Clerk of Court using the CM/ECF system, which will send a notification of such filing to the following: Elizabeth Marie Locke Kirkland & Ellis LLP 655 15th St. N.W., Suite 1200 Washington, DC 20005 Tel.: [phone] Fax: [phone] Email: [e-mail] Craig Crandall Reilly Richard McGettigan Reilly & West PC 1725 Duke St., Suite 600 Alexandria, VA 22314 Tel.: [phone] Fax: [phone] Email: [e-mail] Counsel for GlaxoSmithKline Plaintiffs Joseph D. Wilson Kelley Drye & Warren LLP 3050 K St. N.W., Suite 400 Washington, DC 20007 Tel.: [phone] Fax: [phone] Email: [e-mail] Counsel for Plaintiff Tafas Lauren A. Wetzler Assistant United States Attorney Justin W. Williams U.S. Attorney's Building 2100 Jamieson Avenue Alexandria, VA 22314 Tel.: [phone] Fax: [phone] Email: [e-mail] Counsel for Defendants

__________/s/________________ James M. Dowd (VSB # 41406) WILMER CUTLER PICKERING HALE AND DORR LLP 1875 Pennsylvania Avenue, N.W. Washington, D.C. 20006 Tel.: [phone] Fax: [phone] [e-mail] Attorney for Pharmaceutical Research and Manufacturers of America

3